dc.relation | /*ref*/Ohlstein E, Douglas SA. Endothelin-1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology. Drug Develop Res. 1993; 29: 108-128. 2. Masaki T. Historical review: endothelin. Trends Pharmacol Sci.2004; 25(4): 219-224. 3. Shah R. Endothelins in health and disease. Eur J of Intern Med. 2007; 17: 272-282. 4. Estrada V. Endotelina, un nuevo peptido regulador cardiovas¬cular. [Tesis]. Universidad Complutense de Madrid; 1993. 5. Trow TK, Taichman DB. Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism. Resp Med. 2009; 103: 951-962. 6. Moncada S, Higgs A. The vascular endothelium I. Springer –Verlag Berlin Heidelberg. 2006. 7. Vallance P. Vascular endothelium in human physiology and pathophysiology. Amsterdam: Taylor & Francis e library; 2004. 8. Hynynen M, Khalil R. The vascular endothelin system in hyper¬tension – recent patents and discoveries. Recent pat cardiovasc drug discov. 2006; 1(1): 95-108. 9. Alonso D, Radomski. The nitric oxide – endothelin -1 connection. Heart Fail Rev. 2003; 8: 107-115. 10. Baltazares M, Crespo H, Ortega J, Sotres–Vega A, Baltazares ME. Sistema endotelina. Rev. Inst. Nal. Enf. Resp. Mex . 2005; 18(4): 308-320. 11. Kedzierski RM, Yanagisawa M. Endothelin system: The dou¬ble-edged sword in health and disease. Annu Rev Pharmacol. 2001; 41: 851-876. 12. Jugdutt B.J. The role of nitric oxide in heart failure. Norwell, MA: Kluwer Academic Publishers; 2004. 13. Marasciulo FL, Montagnami M, Potenza MA. Endothelin -1: The yin and yang on vascular function. Curr Med Chem. 2006; 13: 1655-1665. 14. Prasad VS, Palaniswamy C, Frishman W. Endothelin as a clinical target in the treatment of systemic hypertension. Cardiol Rev. 2009; 17: 181-191. 15. La M, Reid JJ. Endothelin -1 and the regulation of vascular tone. Clin Exp Pharmacol P. 1995; 22: 315-323. 16. Rossi GP, Seccia TM, Albertin G, Pessina AC.. Measurement of endothelin: Clinical and research use. Ann Clin Biochem. 2000; 37: 608-626. 17. Melgarejo E. El endotelio 25 años después. Revista Med. 2005; 13(1): 45-61. 18. Toste R, Muscará M. Endothelin receptor antagonists: Another potential alternative for cardiovascular disease. Curr Drug Targets- Cardiovasc Haematol Disord. 2005; 5: 287-301. 19. Masaki T, Kimura S, Goto K. Molecular and vellular mechanism of endothelin regulation. Implications for vascular function. Circulation. 1991; 84: 1457-1468. 20. Masaki T, Yanagisawa M. Cardiovascular effects of the endo¬thelins. Cardiovasc Drug Rev. 1990; 8(4): 373-385. 21. Benigni A, Remuzzi G. Endothelin antagonists. Lancet. 1999; 353: 133-38. 22. Comellas AP, Briva A. Role of endothelin-1 in Acute Lung Injury. Transl Res. 2009; 153: 263-27. 23. Balakrishnan S, Pandhi P. Endothelins: a brief review. Indian J Pharmacol. 1997; 29: 281-288. 24. Scheider MP, Boesen E. I and Pollock DM. Contrasting actions of endothelin eta and etb receptor in cardiovascular disease. Annu. Rev. Pharmacol. Toxicol. 2007; 47: 731-759. 25. Kurtel H, Ghandour S. Endothelins and inflammation: the gastrointestinal system. Pathophysiology. 1999; 6: 77-89. 26. Motte S, McEntee, Naeije R. Endothelin receptor antagonists. Pharmacol Ther. 2006; 110: 386-414. 27. Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007; 76: 8-18. 28. Galié N, Manes A, Brazi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004; 61: 227-237. 29. Leppaluoto J, Ruskoaho H. Endothelin eptides: Biological activies, celular signaling and clinical significance. Ann Med. 1992; 24: 153-161. 30. Agapitov AV, Hayes WG. Role of endothelium in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2002; 3: 1-15. 31. D´Orleans-Juste PD, Houde M, Rae GA. Bkaily G, Carrier E, Simard E. Endothelin-1(1-31): From 1. chymasa-dependet syntesis to cardiovascular pathologies. Vascul Pharmacol. 2008; 49: 51-62. 32. Kirkby NS, Hadoke PW, Bagnall AJ. Webb DJ. The endothelin sytem as a therapeutic target in cardiovascular disease.: great expectations or bleak house? Br J Pharmacol. 2008 ; 153:1105- 1119. 33. Davenport AP. International union of pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev. 2002; 54: 219-226. 34. Neil F. Fisiología de la tonicidad del endotelio vascular y dis¬función del endotelio-parte1. Et vita. 2007; 2(2):18-26. 35. Neil F. Medicina vascular: Implicancias del endotelio en la re¬gulación del tono vascular. Lima: Fondo Editorial UPT-PERU; 2010. 36. Ohlstein EH, Elliot JD, Feuerstein GZ, Ruffolo R. Endothelin receptors: receptor classification, novel receptor antagonists, and potential therapeutic targets. Med ResRev. 1996;16(4): 365-390. 37. Duru F, Barton M, luscher T. F. et al. Endothelin and cardiac arrthythmias: do endothelin antagonists heve a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res. 2001; 49: 272-280. 38. Kim N, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther. 2002; 7(1): 9-19. 39. Savioa C, Schiffrin EL. Significance of recently identified peptides in hypertension: Endothelin, natriuretic pepetides, adrenomedullin, leptin. Med Clin N Am. 2004; 88: 39-62. 40. Heriques T, Olivera S, Leite A. Regulación del tono vascular. Facultad de Medicina de la Universidad de Porto 2002/03. 41. Aliaga R. Reactividad de las arterias coronarias frente a factores vasoactivos derivados del endotelio. Valencia: Universitat de Valencia. Servie de publicacions ; 2005. 42. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J. Physiol. Pharmacol. 2008; 86: 485-498. 43. Schorlemmer A, Matter ML, Shohet RV. Cardioprotective signaling by endothelin. Trends Cardiovasc Med. 2008; 18: 233-239. 44. Gray GA, Battistini B, Webb DJ. Endothelins are potent va¬soconstrictor, and much more besides. Trend Pharmacol Sci. 2000; 21: 38-40. 45. Clozel M, Flores S. Endothelin receptor as drug targets in chronic cardiovascular disease: the rationale for dual antagonism. Drug Develop Res. 2006; 67: 825-834. | |